TRADENAME (TBC) Novartis Pharmaceuticals Australia Pty Ltd

Ianalumab is proposed as a treatment for moderate to severe Sjogren's disease in adult patients. Sjogren's disease is a chronic autoimmune condition, where the immune system mistakenly attacks the body's own healthy tissues, especially the moisture-producing (exocrine) glands, which keep surfaces lubricated. It commonly causes dry eyes and dry mouth but can affect multiple parts of the body.